{"gene":"BCL6B","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":1998,"finding":"BAZF (BCL6B) contains BTB/POZ and Krüppel-like zinc finger domains; it associates with BCL6 via its BTB/POZ domain and localizes to the nucleus. BAZF binds specifically to BCL6 DNA-binding sequences and functions as a transcriptional repressor. Repressor activity is associated with both the BTB/POZ domain and a conserved 17-amino-acid sequence in the middle portion of BAZF.","method":"Co-immunoprecipitation, nuclear localization assay, reporter gene/transcriptional repression assay, domain deletion analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal domain mapping, nuclear localization confirmed, DNA-binding and repression assays with multiple constructs in a single foundational study","pmids":["9632807"],"is_preprint":false},{"year":2001,"finding":"BAZF (BCL6B) binds to a consensus DNA sequence (CBS: 5'-ATTCCTAGAAAG-3') essentially identical to that of BCL6; three nucleotides at positions 6, 8, and 9 are critical for binding. BAZF and BCL6 can also bind STAT6-binding sequences (CD23b, IgE germline ε, IL-4 elements) with weak affinity, and a C-to-T mutation in the IL-4 STAT6-binding element strongly enhances their binding.","method":"Electrophoretic mobility shift assay (EMSA), site-directed mutagenesis of binding sequences","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro binding assay with systematic mutagenesis of critical nucleotides, single lab but multiple orthogonal sequence variants tested","pmids":["11374866"],"is_preprint":false},{"year":2003,"finding":"BAZF (BCL6B) requires BCL6 to exert transcriptional repression: BAZF cannot function as a repressor in BCL6-deficient fibroblasts or BCL6-null cell lines, but repressor activity is restored when the BTB/POZ domain or the middle portion of BCL6 is reintroduced. BAZF does not directly bind mSin3A or HDAC1; instead it recruits the mSin3A/HDAC1 complex indirectly through association with BCL6. Repressor activity is sensitive to the HDAC inhibitor trichostatin A.","method":"Reporter gene assay in BCL6-deficient cells, complementation with BCL6 domain constructs, trichostatin A treatment, co-immunoprecipitation (BTB/POZ and middle-portion binding)","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic complementation in null cell lines combined with domain mapping and pharmacological inhibition, single lab with multiple orthogonal approaches","pmids":["12659862"],"is_preprint":false},{"year":2004,"finding":"BAZF (BCL6B) is required for TCR-triggered proliferation of naive CD4+ T cells but not memory T cells; BAZF-deficient mice show impaired naive CD4+ T cell proliferation to anti-CD3, while lck-BAZF transgenic mice show augmented proliferation. The data suggest BAZF attenuates BCL6's inhibitory effect on naive T cell activation through BCL6/BAZF heterodimer formation.","method":"BAZF-knockout mouse generation, lck-BAZF transgenic mice, T cell proliferation assay with anti-CD3","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KO and transgenic OE with defined cellular phenotype, mechanism proposed (heterodimer) but not directly demonstrated in this paper","pmids":["15314041"],"is_preprint":false},{"year":2005,"finding":"BCL6B is expressed in a subset of antigen-experienced CD8+ T cells. Ectopic BCL6B expression diminishes CD8+ T cell growth in response to IL-2 in vitro. BCL6B-deficient memory CD8+ T cells show a cell-autonomous defect in effector cell numbers generated upon antigen rechallenge (secondary response), while primary responses are normal. BCL6B is therefore required for the enhanced magnitude of the secondary CD8+ T cell response.","method":"BCL6B gene-interrupted mouse model, adoptive transfer/rechallenge assays with vaccinia (H-Y epitope) and influenza (NP peptide), in vitro IL-2 proliferation assay with ectopic BCL6B expression","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function mouse model with defined cellular phenotype confirmed across two independent antigen systems, complemented by in vitro gain-of-function assay","pmids":["15833813"],"is_preprint":false},{"year":2007,"finding":"BAZF (BCL6B)-deficient mice have reduced cycling hematopoietic progenitor cells (HPC) in bone marrow and increased cycling HPC in spleen, mirroring BCL6-deficient mice. HPC from BAZF-deficient mice are resistant to chemokine-induced myelosuppression and lack synergistic response to GM-CSF plus SCF. Depletion of CD8+ T cells in BAZF-deficient mice reverses these hematopoietic defects, indicating BCL6B regulates HPC homeostasis through an indirect CD8+ T cell-dependent pathway.","method":"BAZF-knockout mouse, hematopoietic progenitor colony assays, chemokine suppression assays, CD8+ T cell depletion rescue experiment","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — KO mouse with multiple functional progenitor readouts and rescue experiment identifying CD8+ T cell-dependent mechanism","pmids":["17526724"],"is_preprint":false},{"year":2012,"finding":"BAZF (BCL6B) is induced in endothelial cells by VEGF-A, binds to the Notch signaling factor CBF1, and promotes polyubiquitination-dependent degradation of CBF1 through a BAZF-CUL3 E3 ligase complex. BAZF disruption in vivo reduces tip cell number, filopodia protrusion, and vascular plexus formation in mouse retina (phenotype overlapping Notch activation), and impairs angiogenesis in skin-wound healing.","method":"Co-immunoprecipitation (BAZF-CBF1, BAZF-CUL3), polyubiquitination assay, BAZF-knockout mouse, retinal vascularization analysis, skin wound-healing angiogenesis model","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP defining complex, ubiquitination assay, in vivo KO with two independent angiogenesis phenotypes","pmids":["22279058"],"is_preprint":false},{"year":2012,"finding":"FGF2 activates MAP2K1 (MEK1) signaling to upregulate Bcl6b (and Etv5) in mouse germline stem (GS) cells. An activated form of Map2k1 drives Bcl6b expression and confers FGF2-independent GS cell proliferation. Overexpression of Bcl6b alone in GS cells is sufficient to cause germ cell tumor formation upon transplantation, indicating that excessive Bcl6b-driven self-renewal signals are tumorigenic.","method":"MAP2K1 inhibitor (PD0325901) treatment, activated Map2k1 transfection, Bcl6b/Etv5 transfection into GS cells, in vitro proliferation assay, spermatogonial stem cell transplantation tumor formation assay","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition plus gain-of-function with downstream gene readout and in vivo transplantation outcome, multiple orthogonal approaches","pmids":["22491947"],"is_preprint":false},{"year":2015,"finding":"BCL6B activates p53 signaling in hepatocellular carcinoma cells by increasing EGR1 expression; restoration of BCL6B re-expression suppresses proliferation, induces apoptosis and G1/S arrest, and sensitizes cells to 5-fluorouracil.","method":"5-aza-2'-deoxycytidine re-expression, western blot for EGR1/p53 pathway components, flow cytometry (apoptosis/cell cycle), cell proliferation assay","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — gain-of-function with pathway readout in multiple cell lines, mechanism (BCL6B→EGR1→p53) partially established by protein expression but without direct promoter assay in this study","pmids":["25909168"],"is_preprint":false},{"year":2015,"finding":"BCL6B re-expression in colorectal cancer cells activates p53 signaling, induces apoptosis and G1/S arrest, and inhibits cell invasion and migration. BCL6B sensitizes cells to 5-fluorouracil.","method":"Ectopic BCL6B expression, western blot for p53 pathway, flow cytometry, invasion/migration assays","journal":"American journal of cancer research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — gain-of-function with multiple cellular readouts, consistent with HCC findings, but mechanistic link to p53 is by protein expression not direct promoter binding","pmids":["25973304"],"is_preprint":false},{"year":2018,"finding":"BCL6B overexpression suppresses colorectal carcinoma cell proliferation and migration by inhibiting PI3K/AKT signaling, reducing AKT phosphorylation, downregulating cyclin D1 and MMP-9, and upregulating E-cadherin. These effects are enhanced by the PI3K inhibitor LY294002.","method":"BCL6B transfection, western blot (pAKT), MTT/colony assay, Transwell migration, LY294002 co-treatment","journal":"International journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — gain-of-function with pharmacological pathway validation, single lab, consistent downstream readouts","pmids":["29393377"],"is_preprint":false},{"year":2019,"finding":"ZBTB28 (BCL6B) transactivates TP53 expression by binding to the p53 promoter in competition with BCL6. BCL6 itself is a direct transcriptional target repressed by ZBTB28. ZBTB16 forms heterodimers with ZBTB28 (co-immunoprecipitation) and upregulates ZBTB28 expression to exert tumor suppressor effects.","method":"Luciferase reporter assay (p53 promoter), chromatin immunoprecipitation (ChIP) of ZBTB28 on p53 and BCL6 promoters, co-immunoprecipitation (ZBTB16-ZBTB28), gain-of-function in vitro and xenograft experiments","journal":"Theranostics","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ChIP and luciferase reporter directly demonstrate promoter binding and transcriptional activation/repression, complemented by Co-IP and in vivo data","pmids":["31754389"],"is_preprint":false},{"year":2020,"finding":"ZBTB16 forms heterodimers with ZBTB28 (BCL6B) via co-immunoprecipitation, upregulates ZBTB28, and antagonizes BCL6 transcriptional activity to suppress breast cancer cell proliferation and metastasis. ZBTB16 and ZBTB28 together reverse EMT and inhibit colony formation, migration and invasion.","method":"Co-immunoprecipitation (ZBTB16-ZBTB28), qRT-PCR, luciferase assay, western blot, xenograft, CCK8/Transwell/colony formation assays","journal":"Clinical epigenetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP with luciferase reporter, single lab, consistent with prior reports","pmids":["32517789"],"is_preprint":false},{"year":2021,"finding":"ZBTB28 (BCL6B) induces autophagy in cervical cancer cells by interacting with the autophagy gene FIP200 and by promoting degradation of Bcl-XL, which reduces the Bcl-XL–BECN1 complex. Autophagy induction by ZBTB28 mediates cellular apoptosis through FIP200 regulation.","method":"Ectopic ZBTB28 expression, electron microscopy (autophagosomes), western blot (Bcl-XL, BECN1, FIP200), co-immunoprecipitation or interaction assay, xenograft, flow cytometry","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — interaction with FIP200 and Bcl-XL degradation shown, autophagosome confirmed by EM, single lab","pmids":["33931087"],"is_preprint":false},{"year":2022,"finding":"ZBTB28 (BCL6B) directly regulates IFNAR (interferon-alpha/beta receptor) transcription to activate interferon-stimulated genes. Ectopic ZBTB28 in breast cancer cells downregulates CD24 and CD47 to promote macrophage phagocytosis, demonstrating a role in innate immune surveillance.","method":"Ectopic ZBTB28 expression, qRT-PCR and western blot for IFNAR/ISGs, flow cytometry (CD24/CD47), macrophage phagocytosis assay, xenograft","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct regulatory claim on IFNAR supported by expression data and functional phagocytosis assay, single lab; promoter-binding not explicitly confirmed in abstract","pmids":["35048182"],"is_preprint":false},{"year":2023,"finding":"In retinal endothelial cells, BCL6B expression is induced by VEGF. BCL6B-deficient endothelial cells show Notch signal activation (via CBF1/NICD) and attenuated cord formation by blocking VEGF-VEGFR2 signaling. In BCL6B-knockout mice, breakdown of the inner blood-retinal barrier and pro-angiogenic cytokine induction are abrogated through Notch transcriptional activation. BCL6B-targeting siRNA suppresses choroidal neovascularization lesions and retinal edema in animal models.","method":"BCL6B-KO mice, siRNA knockdown in vascular models, optical coherence tomography, immunostaining for CBF1/NICD/Müller cells, in vitro cord formation assay, cynomolgus monkey choroidal neovascularization model","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mouse plus siRNA knockdown in two disease models with molecular pathway readout (CBF1/NICD), consistent with earlier CUL3/CBF1 mechanism","pmids":["37078291"],"is_preprint":false},{"year":2024,"finding":"BCL6B suppresses endothelial cell (EC) differentiation from human iPSCs by binding to the promoter region of ETV2 and repressing its transcriptional activity, as demonstrated by ChIP-PCR and luciferase reporter assays. Overexpression of ETV2 rescues the BCL6B-mediated block in EC differentiation. BCL6B overexpression also attenuates tubular structure formation and vessel organoid growth.","method":"Doxycycline-inducible hiPSC overexpression/knockdown, luciferase reporter assay (ETV2 promoter), ChIP-PCR (BCL6B on ETV2 promoter), RNA-seq, flow cytometry (EC markers), tube formation assay, vessel organoids","journal":"Stem cell research & therapy","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct promoter occupancy by ChIP and luciferase reporter with genetic rescue, multiple orthogonal methods in one study","pmids":["39075623"],"is_preprint":false},{"year":2026,"finding":"BCL6B directly represses GGT5 transcription by binding to the GGT5 promoter (validated by dual-luciferase reporter and EMSA). Repression of GGT5 by BCL6B modulates MAPK signaling in a GGT5-dependent manner, characterized by decreased ERK phosphorylation and enhanced p38/JNK activation, leading to apoptosis and G0/G1 cell cycle arrest in AML cells.","method":"Dual-luciferase reporter assay, electrophoretic mobility shift assay (EMSA), transcriptome sequencing, western blot (ERK/p38/JNK phosphorylation), gain- and loss-of-function in AML lines, zebrafish and nude mouse xenograft models","journal":"Biology direct","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct DNA binding confirmed by EMSA and luciferase with downstream pathway validation, in vivo models, single lab but multiple orthogonal methods","pmids":["42083053"],"is_preprint":false},{"year":2026,"finding":"ABHD17C-mediated depalmitoylation of BCL6B at Cys442 blocks importin-α/β-mediated nuclear translocation of BCL6B and drives its ubiquitination-dependent degradation in the cytoplasm. Loss of nuclear BCL6B relieves transcriptional repression of the anti-phagocytic signal CD24, increasing its expression and enabling pancreatic cancer cells to evade macrophage phagocytosis.","method":"ABHD17C overexpression/knockdown, palmitoylation assay, site-directed mutagenesis (Cys442), subcellular fractionation, co-immunoprecipitation (importin-α/β), ubiquitination assay, CD24 luciferase reporter, macrophage phagocytosis assay, orthotopic xenograft (NSG mice)","journal":"Advanced science","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — depalmitoylation site mutagenesis, nuclear import mechanism, ubiquitination, and transcriptional reporter all in one study with in vivo validation","pmids":["42154583"],"is_preprint":false}],"current_model":"BCL6B (BAZF/ZBTB28/ZNF62) is a sequence-specific transcriptional repressor that binds BCL6-consensus DNA elements via its Krüppel-like zinc fingers; its BTB/POZ domain mediates homodimerization with BCL6 through which it recruits the mSin3A/HDAC1 co-repressor complex to silence target genes including p53 promoter competitors, ETV2, GGT5, and CD24. Downstream of VEGF/MAP2K1 signaling, BCL6B assembles with Cullin-3 as an E3 ubiquitin ligase to polyubiquitinate and degrade the Notch effector CBF1, thereby coupling VEGF-driven angiogenesis to Notch suppression in endothelial cells. BCL6B nuclear activity is regulated post-translationally: ABHD17C-mediated depalmitoylation at Cys442 blocks importin-α/β-dependent nuclear import and redirects BCL6B to ubiquitin-proteasomal degradation in the cytoplasm. In the immune compartment, BCL6B is required for naive CD4+ T cell activation and for the enhanced magnitude of the memory CD8+ T cell secondary response by transiently repressing IL-2-driven effector differentiation, and it regulates hematopoietic progenitor homeostasis indirectly through CD8+ T cells."},"narrative":{"mechanistic_narrative":"BCL6B (BAZF/ZBTB28/ZNF62) is a sequence-specific transcriptional repressor that recognizes BCL6-consensus DNA elements through its Krüppel-like zinc fingers and silences target genes via its BTB/POZ domain [PMID:9632807, PMID:11374866]. Because BCL6B does not bind co-repressors directly, it heterodimerizes with BCL6 through the BTB/POZ domain and recruits the mSin3A/HDAC1 complex indirectly through that association, rendering its repressor activity HDAC-dependent [PMID:9632807, PMID:12659862]. In tumor contexts BCL6B acts as a tumor suppressor by directly binding promoters: it transactivates TP53 in competition with BCL6 while repressing BCL6 itself, represses GGT5 to remodel MAPK signaling (lowering ERK and raising p38/JNK activity), and represses CD24 [PMID:31754389, PMID:42083053, PMID:42154583]. Independently of its repressor role, VEGF-induced BCL6B assembles with Cullin-3 into an E3 ubiquitin ligase that polyubiquitinates and degrades the Notch effector CBF1, coupling VEGF-driven angiogenesis to Notch suppression in endothelial cells; it also restrains endothelial differentiation by repressing the master factor ETV2 [PMID:22279058, PMID:37078291, PMID:39075623]. BCL6B nuclear activity is gated post-translationally, as ABHD17C-mediated depalmitoylation at Cys442 blocks importin-α/β-dependent nuclear import and routes BCL6B to cytoplasmic proteasomal degradation, derepressing CD24 and enabling immune evasion [PMID:42154583]. In the immune compartment BCL6B is required for naive CD4+ T cell activation and for the enhanced magnitude of memory CD8+ T cell secondary responses, and it regulates hematopoietic progenitor homeostasis indirectly through CD8+ T cells [PMID:15314041, PMID:15833813, PMID:17526724, PMID:22491947].","teleology":[{"year":1998,"claim":"Established BCL6B as a nuclear, BCL6-related transcriptional repressor, defining its core domain architecture and DNA-binding behavior.","evidence":"Co-IP, nuclear localization, reporter repression, and domain-deletion analysis of BAZF","pmids":["9632807"],"confidence":"High","gaps":["Physiological target genes not identified","Functional consequence of BCL6 association not yet mechanistic"]},{"year":2001,"claim":"Defined the precise DNA recognition sequence, showing BCL6B binds a BCL6-identical consensus and can weakly engage STAT6 elements.","evidence":"EMSA with systematic site-directed mutagenesis of binding elements","pmids":["11374866"],"confidence":"High","gaps":["In vitro binding only; genomic occupancy not mapped","Biological targets of STAT6-element binding unclear"]},{"year":2003,"claim":"Resolved how BCL6B represses transcription — it lacks direct co-repressor binding and instead recruits mSin3A/HDAC1 through BCL6 heterodimerization.","evidence":"Reporter complementation in BCL6-null cells, domain mapping, trichostatin A inhibition, Co-IP","pmids":["12659862"],"confidence":"High","gaps":["Whether BCL6B has any BCL6-independent repressive function not addressed","Endogenous target loci not defined"]},{"year":2004,"claim":"Linked BCL6B to adaptive immunity, showing it is required for naive CD4+ T cell proliferation, proposed to act by modulating BCL6 via heterodimers.","evidence":"BAZF-knockout and lck-BAZF transgenic mice, anti-CD3 proliferation assays","pmids":["15314041"],"confidence":"Medium","gaps":["Heterodimer mechanism inferred but not demonstrated in vivo","Target genes in T cells unknown"]},{"year":2005,"claim":"Demonstrated a cell-autonomous role for BCL6B in memory CD8+ T cells, required for the amplified secondary response while sparing primary responses.","evidence":"Gene-interrupted mouse with adoptive transfer/rechallenge across two antigen systems plus in vitro IL-2 assay","pmids":["15833813"],"confidence":"High","gaps":["Transcriptional targets controlling memory expansion not identified","Connection to IL-2 signaling mechanistically undefined"]},{"year":2007,"claim":"Showed BCL6B regulates hematopoietic progenitor homeostasis indirectly, via a CD8+ T cell-dependent pathway rather than progenitor-intrinsic action.","evidence":"BAZF-knockout mouse, progenitor colony/chemokine assays, CD8+ T cell depletion rescue","pmids":["17526724"],"confidence":"High","gaps":["Mediator signals from CD8+ T cells to progenitors unknown","Transcriptional program involved not defined"]},{"year":2012,"claim":"Revealed an enzymatic, non-transcriptional role: VEGF-induced BCL6B forms a CUL3 E3 ligase that degrades the Notch effector CBF1 to drive angiogenesis.","evidence":"Reciprocal Co-IP, polyubiquitination assay, knockout mouse with retinal and wound-healing angiogenesis phenotypes","pmids":["22279058"],"confidence":"High","gaps":["How a BTB-zinc finger repressor switches to an E3 ligase adaptor not structurally resolved","Other CUL3 substrates unexplored"]},{"year":2012,"claim":"Placed BCL6B downstream of FGF2/MAP2K1 signaling in germline stem cells, where excess BCL6B drives self-renewal and is tumorigenic.","evidence":"MAP2K1 inhibition, activated Map2k1 and Bcl6b overexpression, stem cell transplantation tumor assay","pmids":["22491947"],"confidence":"High","gaps":["Direct BCL6B target genes mediating self-renewal not identified","Contrast with tumor-suppressor role in other tissues unexplained"]},{"year":2015,"claim":"Identified BCL6B as a tumor suppressor in carcinomas, activating p53 signaling to induce apoptosis and cell-cycle arrest and sensitize to 5-FU.","evidence":"Re-expression after demethylation and ectopic expression in HCC and colorectal lines, p53-pathway readouts, flow cytometry, invasion assays","pmids":["25909168","25973304"],"confidence":"Medium","gaps":["p53 activation shown by protein expression, not direct promoter assay in these studies","EGR1 intermediary not mechanistically dissected"]},{"year":2018,"claim":"Extended tumor-suppressor mechanism to PI3K/AKT inhibition, reducing cyclin D1/MMP-9 and restoring E-cadherin in colorectal cells.","evidence":"BCL6B transfection with pAKT readout and LY294002 co-treatment, proliferation and migration assays","pmids":["29393377"],"confidence":"Medium","gaps":["Direct versus indirect effect on PI3K/AKT not distinguished","Single-lab, no in vivo validation"]},{"year":2019,"claim":"Provided direct promoter-level proof of the BCL6B/BCL6 antagonism: BCL6B binds and transactivates TP53 while repressing BCL6, and is upregulated by ZBTB16.","evidence":"ChIP and luciferase reporters on p53/BCL6 promoters, ZBTB16-ZBTB28 Co-IP, xenografts","pmids":["31754389"],"confidence":"High","gaps":["Whether p53 transactivation requires HDAC complex or is repressor-independent unclear","Genome-wide occupancy not mapped"]},{"year":2020,"claim":"Reinforced the ZBTB16-BCL6B partnership as a tumor-suppressive axis antagonizing BCL6 to reverse EMT in breast cancer.","evidence":"Reciprocal Co-IP, luciferase, xenografts, migration/invasion/colony assays","pmids":["32517789"],"confidence":"Medium","gaps":["Direct EMT target genes not defined","Single-lab confirmation"]},{"year":2021,"claim":"Connected BCL6B to autophagy-dependent apoptosis through FIP200 interaction and Bcl-XL degradation, disrupting the Bcl-XL–BECN1 complex.","evidence":"Ectopic ZBTB28 expression, EM autophagosome detection, interaction/Co-IP, xenograft, flow cytometry","pmids":["33931087"],"confidence":"Medium","gaps":["Mechanism linking transcriptional repressor to Bcl-XL degradation unresolved","FIP200 binding interface undefined"]},{"year":2022,"claim":"Implicated BCL6B in innate immune surveillance by regulating IFNAR transcription and downregulating anti-phagocytic CD24/CD47 to promote macrophage phagocytosis.","evidence":"Ectopic ZBTB28 expression, IFNAR/ISG expression, flow cytometry, phagocytosis assay, xenograft","pmids":["35048182"],"confidence":"Medium","gaps":["Direct promoter binding to IFNAR not confirmed","Relative contributions of CD24 vs CD47 unclear"]},{"year":2023,"claim":"Confirmed the angiogenic VEGF–BCL6B–Notch axis in retinal disease, where BCL6B loss activates Notch and BCL6B siRNA suppresses neovascular pathology.","evidence":"Knockout mice and siRNA in choroidal neovascularization and blood-retinal barrier models, CBF1/NICD readouts, monkey CNV model","pmids":["37078291"],"confidence":"High","gaps":["Therapeutic window and off-target effects of BCL6B knockdown unaddressed","Interplay of E3 ligase and repressor functions in this setting unresolved"]},{"year":2024,"claim":"Showed BCL6B gates endothelial cell fate by directly repressing the master EC factor ETV2, with ETV2 overexpression rescuing the differentiation block.","evidence":"Inducible hiPSC over/knockdown, ETV2 promoter ChIP-PCR and luciferase, RNA-seq, tube formation, vessel organoids, genetic rescue","pmids":["39075623"],"confidence":"High","gaps":["Upstream signals controlling BCL6B in this program not defined","Whether ETV2 repression uses BCL6/HDAC machinery untested"]},{"year":2026,"claim":"Defined a direct BCL6B–GGT5 repression event reshaping MAPK signaling toward apoptosis and arrest in AML, with direct DNA binding confirmed.","evidence":"Dual-luciferase, EMSA, RNA-seq, ERK/p38/JNK westerns, gain/loss-of-function in AML, zebrafish and mouse xenografts","pmids":["42083053"],"confidence":"High","gaps":["How GGT5 loss biases MAPK branch selection mechanistically unclear","Whether GGT5 axis operates outside AML untested"]},{"year":2026,"claim":"Established post-translational control of BCL6B localization: ABHD17C depalmitoylation at Cys442 blocks importin-α/β nuclear import and triggers cytoplasmic degradation, derepressing CD24 for immune evasion.","evidence":"ABHD17C over/knockdown, palmitoylation and Cys442 mutagenesis, fractionation, importin Co-IP, ubiquitination assay, CD24 reporter, phagocytosis assay, orthotopic xenograft","pmids":["42154583"],"confidence":"High","gaps":["The palmitoyltransferase opposing ABHD17C not identified","Whether this regulation generalizes beyond pancreatic cancer untested"]},{"year":null,"claim":"It remains unresolved how BCL6B's distinct activities — BCL6-dependent transcriptional repression, BCL6-independent promoter transactivation of TP53, and CUL3-dependent E3 ligase function — are partitioned across cell types and whether common structural determinants or post-translational signals select between them.","evidence":"","pmids":[],"confidence":"High","gaps":["No structural model integrating repressor and E3-adaptor roles","Genome-wide occupancy and direct target catalog incomplete","Context-switch between tumor-suppressor and self-renewal/tumorigenic roles unexplained"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,1,11,16,17]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,11,16,17]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[6]},{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[6]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,18]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[18]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2,11,16,17]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[6,10,15,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,5,14]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[6,15,16]}],"complexes":["BCL6B-CUL3 E3 ubiquitin ligase complex","mSin3A/HDAC1 co-repressor complex (recruited via BCL6)"],"partners":["BCL6","CUL3","CBF1","ZBTB16","FIP200","ABHD17C","KPNA (IMPORTIN-ALPHA)"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8N143","full_name":"B-cell CLL/lymphoma 6 member B protein","aliases":["Bcl6-associated zinc finger protein","Zinc finger protein 62"],"length_aa":479,"mass_kda":51.5,"function":"Acts as a sequence-specific transcriptional repressor in association with BCL6. May function in a narrow stage or be related to some events in the early B-cell development","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q8N143/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BCL6B","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BCL6B","total_profiled":1310},"omim":[{"mim_id":"608992","title":"BCL6B TRANSCRIPTION REPRESSOR; BCL6B","url":"https://www.omim.org/entry/608992"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BCL6B"},"hgnc":{"alias_symbol":["ZBTB28","BAZF"],"prev_symbol":["ZNF62"]},"alphafold":{"accession":"Q8N143","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8N143","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8N143-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8N143-F1-predicted_aligned_error_v6.png","plddt_mean":54.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BCL6B","jax_strain_url":"https://www.jax.org/strain/search?query=BCL6B"},"sequence":{"accession":"Q8N143","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8N143.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8N143/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8N143"}},"corpus_meta":[{"pmid":"22491947","id":"PMC_22491947","title":"FGF2 mediates mouse spermatogonial stem cell self-renewal via upregulation of Etv5 and Bcl6b through MAP2K1 activation.","date":"2012","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/22491947","citation_count":171,"is_preprint":false},{"pmid":"9632807","id":"PMC_9632807","title":"BAZF, a novel Bcl6 homolog, functions as a transcriptional repressor.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9632807","citation_count":73,"is_preprint":false},{"pmid":"15833813","id":"PMC_15833813","title":"BCL6b mediates the enhanced magnitude of the secondary response of memory CD8+ T lymphocytes.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15833813","citation_count":66,"is_preprint":false},{"pmid":"22279058","id":"PMC_22279058","title":"BAZF, a novel component of cullin3-based E3 ligase complex, mediates VEGFR and Notch cross-signaling in angiogenesis.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22279058","citation_count":51,"is_preprint":false},{"pmid":"32517789","id":"PMC_32517789","title":"BTB/POZ zinc finger protein ZBTB16 inhibits breast cancer proliferation and metastasis through upregulating ZBTB28 and antagonizing BCL6/ZBTB27.","date":"2020","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/32517789","citation_count":43,"is_preprint":false},{"pmid":"11374866","id":"PMC_11374866","title":"Binding of BAZF and Bc16 to STAT6-binding DNA sequences.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11374866","citation_count":39,"is_preprint":false},{"pmid":"31754389","id":"PMC_31754389","title":"Tumor suppressive BTB/POZ zinc-finger protein ZBTB28 inhibits oncogenic BCL6/ZBTB27 signaling to maintain p53 transcription in multiple carcinogenesis.","date":"2019","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31754389","citation_count":33,"is_preprint":false},{"pmid":"25909168","id":"PMC_25909168","title":"Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25909168","citation_count":31,"is_preprint":false},{"pmid":"25973304","id":"PMC_25973304","title":"Epigenetic silencing BCL6B induced colorectal cancer proliferation and metastasis by inhibiting P53 signaling.","date":"2015","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25973304","citation_count":26,"is_preprint":false},{"pmid":"35048182","id":"PMC_35048182","title":"ZBTB28 inhibits breast cancer by activating IFNAR and dual blocking CD24 and CD47 to enhance macrophages phagocytosis.","date":"2022","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/35048182","citation_count":25,"is_preprint":false},{"pmid":"17526724","id":"PMC_17526724","title":"Aberrant regulation of hematopoiesis by T cells in BAZF-deficient mice.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17526724","citation_count":22,"is_preprint":false},{"pmid":"24191714","id":"PMC_24191714","title":"Promoter hypermethylation of BCL6B gene is a potential plasma DNA biomarker for gastric cancer.","date":"2013","source":"Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/24191714","citation_count":22,"is_preprint":false},{"pmid":"12659862","id":"PMC_12659862","title":"Bcl6-dependent transcriptional repression by BAZF.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12659862","citation_count":22,"is_preprint":false},{"pmid":"11855826","id":"PMC_11855826","title":"Cloning and characterization of the human BAZF gene, a homologue of the BCL6 oncogene.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11855826","citation_count":21,"is_preprint":false},{"pmid":"33931087","id":"PMC_33931087","title":"ZBTB28 induces autophagy by regulation of FIP200 and Bcl-XL facilitating cervical cancer cell apoptosis.","date":"2021","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/33931087","citation_count":21,"is_preprint":false},{"pmid":"15314041","id":"PMC_15314041","title":"BAZF is required for activation of naive CD4 T cells by TCR triggering.","date":"2004","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15314041","citation_count":20,"is_preprint":false},{"pmid":"25970780","id":"PMC_25970780","title":"BCL6B expression in hepatocellular carcinoma and its efficacy in the inhibition of liver damage and fibrogenesis.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25970780","citation_count":15,"is_preprint":false},{"pmid":"30195499","id":"PMC_30195499","title":"Silymarin amplifies apoptosis in ectopic endometrial tissue in rats with endometriosis; implication on growth factor GDNF, ERK1/2 and Bcl-6b expression.","date":"2018","source":"Acta histochemica","url":"https://pubmed.ncbi.nlm.nih.gov/30195499","citation_count":15,"is_preprint":false},{"pmid":"29393377","id":"PMC_29393377","title":"BCL6B suppresses proliferation and migration of colorectal carcinoma cells through inhibition of the PI3K/AKT signaling pathway.","date":"2018","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29393377","citation_count":13,"is_preprint":false},{"pmid":"31288844","id":"PMC_31288844","title":"Inhibition of Bcl6b promotes gastric cancer by amplifying inflammation in mice.","date":"2019","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/31288844","citation_count":11,"is_preprint":false},{"pmid":"37078291","id":"PMC_37078291","title":"BCL6B Contributes to Ocular Vascular Diseases via Notch Signal Silencing.","date":"2023","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/37078291","citation_count":10,"is_preprint":false},{"pmid":"39075623","id":"PMC_39075623","title":"BCL6B-dependent suppression of ETV2 hampers endothelial cell differentiation.","date":"2024","source":"Stem cell research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/39075623","citation_count":7,"is_preprint":false},{"pmid":"36376550","id":"PMC_36376550","title":"CircTFF1 Promotes Proliferation, Migration and Invasion of Lung Cancer Cells by Facilitating Methylation of BCL6B Promoter via miR-29c-3p/DNMT3A Axis.","date":"2022","source":"Molecular biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/36376550","citation_count":7,"is_preprint":false},{"pmid":"36209951","id":"PMC_36209951","title":"Carob extract induces spermatogenesis in an infertile mouse model via upregulation of Prm1, Plzf, Bcl-6b, Dazl, Ngn3, Stra8, and Smc1b.","date":"2022","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36209951","citation_count":7,"is_preprint":false},{"pmid":"30292753","id":"PMC_30292753","title":"Expression of the alternative splicing variants of bcl6b in medaka Oryzias latipes.","date":"2018","source":"Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30292753","citation_count":6,"is_preprint":false},{"pmid":"40695624","id":"PMC_40695624","title":"Metformin suppresses the mitochondrial and transcriptional response to exercise, revealing a conserved BCL6B-associated angiogenic program.","date":"2025","source":"Journal of applied physiology (Bethesda, Md. : 1985)","url":"https://pubmed.ncbi.nlm.nih.gov/40695624","citation_count":6,"is_preprint":false},{"pmid":"34161675","id":"PMC_34161675","title":"Epigenetic silencing of ZBTB28 promotes renal cell carcinogenesis.","date":"2021","source":"Asia-Pacific journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34161675","citation_count":2,"is_preprint":false},{"pmid":"41049002","id":"PMC_41049002","title":"Insight into the Role of the BCL6B Gene in Biological Functions and Disease Progression.","date":"2025","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/41049002","citation_count":1,"is_preprint":false},{"pmid":"41200855","id":"PMC_41200855","title":"Distinct roles of Atf3, Zfp711 and Bcl6b in early embryonic hematopoietic and endothelial lineage specification.","date":"2025","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/41200855","citation_count":1,"is_preprint":false},{"pmid":"39756899","id":"PMC_39756899","title":"[The potential of BCL6B as a therapeutic target for chorioretinal vascular lesions].","date":"2025","source":"Nihon yakurigaku zasshi. Folia pharmacologica Japonica","url":"https://pubmed.ncbi.nlm.nih.gov/39756899","citation_count":0,"is_preprint":false},{"pmid":"42083053","id":"PMC_42083053","title":"BCL6B suppresses acute myeloid leukemia progression by transcriptionally repressing GGT5 and modulating MAPK signaling.","date":"2026","source":"Biology direct","url":"https://pubmed.ncbi.nlm.nih.gov/42083053","citation_count":0,"is_preprint":false},{"pmid":"42154583","id":"PMC_42154583","title":"ABHD17C-Mediated S-Depalmitoylation of BCL6B Enhances CD24 Transcription to Resist Macrophage Phagocytosis in Pancreatic Cancer.","date":"2026","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/42154583","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.02.23.639715","title":"Single-Cell Roadmap of Early Hemato-Endothelial Development: Functions of Atf3, Zfp711 and Bcl6b","date":"2025-02-25","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.23.639715","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":19674,"output_tokens":5659,"usd":0.071954,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14135,"output_tokens":5451,"usd":0.103475,"stage2_stop_reason":"end_turn"},"total_usd":0.175429,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"BAZF (BCL6B) contains BTB/POZ and Krüppel-like zinc finger domains; it associates with BCL6 via its BTB/POZ domain and localizes to the nucleus. BAZF binds specifically to BCL6 DNA-binding sequences and functions as a transcriptional repressor. Repressor activity is associated with both the BTB/POZ domain and a conserved 17-amino-acid sequence in the middle portion of BAZF.\",\n      \"method\": \"Co-immunoprecipitation, nuclear localization assay, reporter gene/transcriptional repression assay, domain deletion analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal domain mapping, nuclear localization confirmed, DNA-binding and repression assays with multiple constructs in a single foundational study\",\n      \"pmids\": [\"9632807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"BAZF (BCL6B) binds to a consensus DNA sequence (CBS: 5'-ATTCCTAGAAAG-3') essentially identical to that of BCL6; three nucleotides at positions 6, 8, and 9 are critical for binding. BAZF and BCL6 can also bind STAT6-binding sequences (CD23b, IgE germline ε, IL-4 elements) with weak affinity, and a C-to-T mutation in the IL-4 STAT6-binding element strongly enhances their binding.\",\n      \"method\": \"Electrophoretic mobility shift assay (EMSA), site-directed mutagenesis of binding sequences\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro binding assay with systematic mutagenesis of critical nucleotides, single lab but multiple orthogonal sequence variants tested\",\n      \"pmids\": [\"11374866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"BAZF (BCL6B) requires BCL6 to exert transcriptional repression: BAZF cannot function as a repressor in BCL6-deficient fibroblasts or BCL6-null cell lines, but repressor activity is restored when the BTB/POZ domain or the middle portion of BCL6 is reintroduced. BAZF does not directly bind mSin3A or HDAC1; instead it recruits the mSin3A/HDAC1 complex indirectly through association with BCL6. Repressor activity is sensitive to the HDAC inhibitor trichostatin A.\",\n      \"method\": \"Reporter gene assay in BCL6-deficient cells, complementation with BCL6 domain constructs, trichostatin A treatment, co-immunoprecipitation (BTB/POZ and middle-portion binding)\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic complementation in null cell lines combined with domain mapping and pharmacological inhibition, single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"12659862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"BAZF (BCL6B) is required for TCR-triggered proliferation of naive CD4+ T cells but not memory T cells; BAZF-deficient mice show impaired naive CD4+ T cell proliferation to anti-CD3, while lck-BAZF transgenic mice show augmented proliferation. The data suggest BAZF attenuates BCL6's inhibitory effect on naive T cell activation through BCL6/BAZF heterodimer formation.\",\n      \"method\": \"BAZF-knockout mouse generation, lck-BAZF transgenic mice, T cell proliferation assay with anti-CD3\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO and transgenic OE with defined cellular phenotype, mechanism proposed (heterodimer) but not directly demonstrated in this paper\",\n      \"pmids\": [\"15314041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"BCL6B is expressed in a subset of antigen-experienced CD8+ T cells. Ectopic BCL6B expression diminishes CD8+ T cell growth in response to IL-2 in vitro. BCL6B-deficient memory CD8+ T cells show a cell-autonomous defect in effector cell numbers generated upon antigen rechallenge (secondary response), while primary responses are normal. BCL6B is therefore required for the enhanced magnitude of the secondary CD8+ T cell response.\",\n      \"method\": \"BCL6B gene-interrupted mouse model, adoptive transfer/rechallenge assays with vaccinia (H-Y epitope) and influenza (NP peptide), in vitro IL-2 proliferation assay with ectopic BCL6B expression\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function mouse model with defined cellular phenotype confirmed across two independent antigen systems, complemented by in vitro gain-of-function assay\",\n      \"pmids\": [\"15833813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"BAZF (BCL6B)-deficient mice have reduced cycling hematopoietic progenitor cells (HPC) in bone marrow and increased cycling HPC in spleen, mirroring BCL6-deficient mice. HPC from BAZF-deficient mice are resistant to chemokine-induced myelosuppression and lack synergistic response to GM-CSF plus SCF. Depletion of CD8+ T cells in BAZF-deficient mice reverses these hematopoietic defects, indicating BCL6B regulates HPC homeostasis through an indirect CD8+ T cell-dependent pathway.\",\n      \"method\": \"BAZF-knockout mouse, hematopoietic progenitor colony assays, chemokine suppression assays, CD8+ T cell depletion rescue experiment\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse with multiple functional progenitor readouts and rescue experiment identifying CD8+ T cell-dependent mechanism\",\n      \"pmids\": [\"17526724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BAZF (BCL6B) is induced in endothelial cells by VEGF-A, binds to the Notch signaling factor CBF1, and promotes polyubiquitination-dependent degradation of CBF1 through a BAZF-CUL3 E3 ligase complex. BAZF disruption in vivo reduces tip cell number, filopodia protrusion, and vascular plexus formation in mouse retina (phenotype overlapping Notch activation), and impairs angiogenesis in skin-wound healing.\",\n      \"method\": \"Co-immunoprecipitation (BAZF-CBF1, BAZF-CUL3), polyubiquitination assay, BAZF-knockout mouse, retinal vascularization analysis, skin wound-healing angiogenesis model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP defining complex, ubiquitination assay, in vivo KO with two independent angiogenesis phenotypes\",\n      \"pmids\": [\"22279058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FGF2 activates MAP2K1 (MEK1) signaling to upregulate Bcl6b (and Etv5) in mouse germline stem (GS) cells. An activated form of Map2k1 drives Bcl6b expression and confers FGF2-independent GS cell proliferation. Overexpression of Bcl6b alone in GS cells is sufficient to cause germ cell tumor formation upon transplantation, indicating that excessive Bcl6b-driven self-renewal signals are tumorigenic.\",\n      \"method\": \"MAP2K1 inhibitor (PD0325901) treatment, activated Map2k1 transfection, Bcl6b/Etv5 transfection into GS cells, in vitro proliferation assay, spermatogonial stem cell transplantation tumor formation assay\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition plus gain-of-function with downstream gene readout and in vivo transplantation outcome, multiple orthogonal approaches\",\n      \"pmids\": [\"22491947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BCL6B activates p53 signaling in hepatocellular carcinoma cells by increasing EGR1 expression; restoration of BCL6B re-expression suppresses proliferation, induces apoptosis and G1/S arrest, and sensitizes cells to 5-fluorouracil.\",\n      \"method\": \"5-aza-2'-deoxycytidine re-expression, western blot for EGR1/p53 pathway components, flow cytometry (apoptosis/cell cycle), cell proliferation assay\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — gain-of-function with pathway readout in multiple cell lines, mechanism (BCL6B→EGR1→p53) partially established by protein expression but without direct promoter assay in this study\",\n      \"pmids\": [\"25909168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BCL6B re-expression in colorectal cancer cells activates p53 signaling, induces apoptosis and G1/S arrest, and inhibits cell invasion and migration. BCL6B sensitizes cells to 5-fluorouracil.\",\n      \"method\": \"Ectopic BCL6B expression, western blot for p53 pathway, flow cytometry, invasion/migration assays\",\n      \"journal\": \"American journal of cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — gain-of-function with multiple cellular readouts, consistent with HCC findings, but mechanistic link to p53 is by protein expression not direct promoter binding\",\n      \"pmids\": [\"25973304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BCL6B overexpression suppresses colorectal carcinoma cell proliferation and migration by inhibiting PI3K/AKT signaling, reducing AKT phosphorylation, downregulating cyclin D1 and MMP-9, and upregulating E-cadherin. These effects are enhanced by the PI3K inhibitor LY294002.\",\n      \"method\": \"BCL6B transfection, western blot (pAKT), MTT/colony assay, Transwell migration, LY294002 co-treatment\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — gain-of-function with pharmacological pathway validation, single lab, consistent downstream readouts\",\n      \"pmids\": [\"29393377\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ZBTB28 (BCL6B) transactivates TP53 expression by binding to the p53 promoter in competition with BCL6. BCL6 itself is a direct transcriptional target repressed by ZBTB28. ZBTB16 forms heterodimers with ZBTB28 (co-immunoprecipitation) and upregulates ZBTB28 expression to exert tumor suppressor effects.\",\n      \"method\": \"Luciferase reporter assay (p53 promoter), chromatin immunoprecipitation (ChIP) of ZBTB28 on p53 and BCL6 promoters, co-immunoprecipitation (ZBTB16-ZBTB28), gain-of-function in vitro and xenograft experiments\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP and luciferase reporter directly demonstrate promoter binding and transcriptional activation/repression, complemented by Co-IP and in vivo data\",\n      \"pmids\": [\"31754389\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ZBTB16 forms heterodimers with ZBTB28 (BCL6B) via co-immunoprecipitation, upregulates ZBTB28, and antagonizes BCL6 transcriptional activity to suppress breast cancer cell proliferation and metastasis. ZBTB16 and ZBTB28 together reverse EMT and inhibit colony formation, migration and invasion.\",\n      \"method\": \"Co-immunoprecipitation (ZBTB16-ZBTB28), qRT-PCR, luciferase assay, western blot, xenograft, CCK8/Transwell/colony formation assays\",\n      \"journal\": \"Clinical epigenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP with luciferase reporter, single lab, consistent with prior reports\",\n      \"pmids\": [\"32517789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ZBTB28 (BCL6B) induces autophagy in cervical cancer cells by interacting with the autophagy gene FIP200 and by promoting degradation of Bcl-XL, which reduces the Bcl-XL–BECN1 complex. Autophagy induction by ZBTB28 mediates cellular apoptosis through FIP200 regulation.\",\n      \"method\": \"Ectopic ZBTB28 expression, electron microscopy (autophagosomes), western blot (Bcl-XL, BECN1, FIP200), co-immunoprecipitation or interaction assay, xenograft, flow cytometry\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — interaction with FIP200 and Bcl-XL degradation shown, autophagosome confirmed by EM, single lab\",\n      \"pmids\": [\"33931087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZBTB28 (BCL6B) directly regulates IFNAR (interferon-alpha/beta receptor) transcription to activate interferon-stimulated genes. Ectopic ZBTB28 in breast cancer cells downregulates CD24 and CD47 to promote macrophage phagocytosis, demonstrating a role in innate immune surveillance.\",\n      \"method\": \"Ectopic ZBTB28 expression, qRT-PCR and western blot for IFNAR/ISGs, flow cytometry (CD24/CD47), macrophage phagocytosis assay, xenograft\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct regulatory claim on IFNAR supported by expression data and functional phagocytosis assay, single lab; promoter-binding not explicitly confirmed in abstract\",\n      \"pmids\": [\"35048182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In retinal endothelial cells, BCL6B expression is induced by VEGF. BCL6B-deficient endothelial cells show Notch signal activation (via CBF1/NICD) and attenuated cord formation by blocking VEGF-VEGFR2 signaling. In BCL6B-knockout mice, breakdown of the inner blood-retinal barrier and pro-angiogenic cytokine induction are abrogated through Notch transcriptional activation. BCL6B-targeting siRNA suppresses choroidal neovascularization lesions and retinal edema in animal models.\",\n      \"method\": \"BCL6B-KO mice, siRNA knockdown in vascular models, optical coherence tomography, immunostaining for CBF1/NICD/Müller cells, in vitro cord formation assay, cynomolgus monkey choroidal neovascularization model\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mouse plus siRNA knockdown in two disease models with molecular pathway readout (CBF1/NICD), consistent with earlier CUL3/CBF1 mechanism\",\n      \"pmids\": [\"37078291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCL6B suppresses endothelial cell (EC) differentiation from human iPSCs by binding to the promoter region of ETV2 and repressing its transcriptional activity, as demonstrated by ChIP-PCR and luciferase reporter assays. Overexpression of ETV2 rescues the BCL6B-mediated block in EC differentiation. BCL6B overexpression also attenuates tubular structure formation and vessel organoid growth.\",\n      \"method\": \"Doxycycline-inducible hiPSC overexpression/knockdown, luciferase reporter assay (ETV2 promoter), ChIP-PCR (BCL6B on ETV2 promoter), RNA-seq, flow cytometry (EC markers), tube formation assay, vessel organoids\",\n      \"journal\": \"Stem cell research & therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct promoter occupancy by ChIP and luciferase reporter with genetic rescue, multiple orthogonal methods in one study\",\n      \"pmids\": [\"39075623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"BCL6B directly represses GGT5 transcription by binding to the GGT5 promoter (validated by dual-luciferase reporter and EMSA). Repression of GGT5 by BCL6B modulates MAPK signaling in a GGT5-dependent manner, characterized by decreased ERK phosphorylation and enhanced p38/JNK activation, leading to apoptosis and G0/G1 cell cycle arrest in AML cells.\",\n      \"method\": \"Dual-luciferase reporter assay, electrophoretic mobility shift assay (EMSA), transcriptome sequencing, western blot (ERK/p38/JNK phosphorylation), gain- and loss-of-function in AML lines, zebrafish and nude mouse xenograft models\",\n      \"journal\": \"Biology direct\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct DNA binding confirmed by EMSA and luciferase with downstream pathway validation, in vivo models, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"42083053\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"ABHD17C-mediated depalmitoylation of BCL6B at Cys442 blocks importin-α/β-mediated nuclear translocation of BCL6B and drives its ubiquitination-dependent degradation in the cytoplasm. Loss of nuclear BCL6B relieves transcriptional repression of the anti-phagocytic signal CD24, increasing its expression and enabling pancreatic cancer cells to evade macrophage phagocytosis.\",\n      \"method\": \"ABHD17C overexpression/knockdown, palmitoylation assay, site-directed mutagenesis (Cys442), subcellular fractionation, co-immunoprecipitation (importin-α/β), ubiquitination assay, CD24 luciferase reporter, macrophage phagocytosis assay, orthotopic xenograft (NSG mice)\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — depalmitoylation site mutagenesis, nuclear import mechanism, ubiquitination, and transcriptional reporter all in one study with in vivo validation\",\n      \"pmids\": [\"42154583\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BCL6B (BAZF/ZBTB28/ZNF62) is a sequence-specific transcriptional repressor that binds BCL6-consensus DNA elements via its Krüppel-like zinc fingers; its BTB/POZ domain mediates homodimerization with BCL6 through which it recruits the mSin3A/HDAC1 co-repressor complex to silence target genes including p53 promoter competitors, ETV2, GGT5, and CD24. Downstream of VEGF/MAP2K1 signaling, BCL6B assembles with Cullin-3 as an E3 ubiquitin ligase to polyubiquitinate and degrade the Notch effector CBF1, thereby coupling VEGF-driven angiogenesis to Notch suppression in endothelial cells. BCL6B nuclear activity is regulated post-translationally: ABHD17C-mediated depalmitoylation at Cys442 blocks importin-α/β-dependent nuclear import and redirects BCL6B to ubiquitin-proteasomal degradation in the cytoplasm. In the immune compartment, BCL6B is required for naive CD4+ T cell activation and for the enhanced magnitude of the memory CD8+ T cell secondary response by transiently repressing IL-2-driven effector differentiation, and it regulates hematopoietic progenitor homeostasis indirectly through CD8+ T cells.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BCL6B (BAZF/ZBTB28/ZNF62) is a sequence-specific transcriptional repressor that recognizes BCL6-consensus DNA elements through its Krüppel-like zinc fingers and silences target genes via its BTB/POZ domain [#0, #1]. Because BCL6B does not bind co-repressors directly, it heterodimerizes with BCL6 through the BTB/POZ domain and recruits the mSin3A/HDAC1 complex indirectly through that association, rendering its repressor activity HDAC-dependent [#0, #2]. In tumor contexts BCL6B acts as a tumor suppressor by directly binding promoters: it transactivates TP53 in competition with BCL6 while repressing BCL6 itself, represses GGT5 to remodel MAPK signaling (lowering ERK and raising p38/JNK activity), and represses CD24 [#11, #17, #18]. Independently of its repressor role, VEGF-induced BCL6B assembles with Cullin-3 into an E3 ubiquitin ligase that polyubiquitinates and degrades the Notch effector CBF1, coupling VEGF-driven angiogenesis to Notch suppression in endothelial cells; it also restrains endothelial differentiation by repressing the master factor ETV2 [#6, #15, #16]. BCL6B nuclear activity is gated post-translationally, as ABHD17C-mediated depalmitoylation at Cys442 blocks importin-α/β-dependent nuclear import and routes BCL6B to cytoplasmic proteasomal degradation, derepressing CD24 and enabling immune evasion [#18]. In the immune compartment BCL6B is required for naive CD4+ T cell activation and for the enhanced magnitude of memory CD8+ T cell secondary responses, and it regulates hematopoietic progenitor homeostasis indirectly through CD8+ T cells [#3, #4, #5, #7].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established BCL6B as a nuclear, BCL6-related transcriptional repressor, defining its core domain architecture and DNA-binding behavior.\",\n      \"evidence\": \"Co-IP, nuclear localization, reporter repression, and domain-deletion analysis of BAZF\",\n      \"pmids\": [\"9632807\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological target genes not identified\", \"Functional consequence of BCL6 association not yet mechanistic\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined the precise DNA recognition sequence, showing BCL6B binds a BCL6-identical consensus and can weakly engage STAT6 elements.\",\n      \"evidence\": \"EMSA with systematic site-directed mutagenesis of binding elements\",\n      \"pmids\": [\"11374866\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vitro binding only; genomic occupancy not mapped\", \"Biological targets of STAT6-element binding unclear\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Resolved how BCL6B represses transcription — it lacks direct co-repressor binding and instead recruits mSin3A/HDAC1 through BCL6 heterodimerization.\",\n      \"evidence\": \"Reporter complementation in BCL6-null cells, domain mapping, trichostatin A inhibition, Co-IP\",\n      \"pmids\": [\"12659862\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BCL6B has any BCL6-independent repressive function not addressed\", \"Endogenous target loci not defined\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Linked BCL6B to adaptive immunity, showing it is required for naive CD4+ T cell proliferation, proposed to act by modulating BCL6 via heterodimers.\",\n      \"evidence\": \"BAZF-knockout and lck-BAZF transgenic mice, anti-CD3 proliferation assays\",\n      \"pmids\": [\"15314041\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Heterodimer mechanism inferred but not demonstrated in vivo\", \"Target genes in T cells unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrated a cell-autonomous role for BCL6B in memory CD8+ T cells, required for the amplified secondary response while sparing primary responses.\",\n      \"evidence\": \"Gene-interrupted mouse with adoptive transfer/rechallenge across two antigen systems plus in vitro IL-2 assay\",\n      \"pmids\": [\"15833813\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional targets controlling memory expansion not identified\", \"Connection to IL-2 signaling mechanistically undefined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed BCL6B regulates hematopoietic progenitor homeostasis indirectly, via a CD8+ T cell-dependent pathway rather than progenitor-intrinsic action.\",\n      \"evidence\": \"BAZF-knockout mouse, progenitor colony/chemokine assays, CD8+ T cell depletion rescue\",\n      \"pmids\": [\"17526724\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mediator signals from CD8+ T cells to progenitors unknown\", \"Transcriptional program involved not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Revealed an enzymatic, non-transcriptional role: VEGF-induced BCL6B forms a CUL3 E3 ligase that degrades the Notch effector CBF1 to drive angiogenesis.\",\n      \"evidence\": \"Reciprocal Co-IP, polyubiquitination assay, knockout mouse with retinal and wound-healing angiogenesis phenotypes\",\n      \"pmids\": [\"22279058\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a BTB-zinc finger repressor switches to an E3 ligase adaptor not structurally resolved\", \"Other CUL3 substrates unexplored\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Placed BCL6B downstream of FGF2/MAP2K1 signaling in germline stem cells, where excess BCL6B drives self-renewal and is tumorigenic.\",\n      \"evidence\": \"MAP2K1 inhibition, activated Map2k1 and Bcl6b overexpression, stem cell transplantation tumor assay\",\n      \"pmids\": [\"22491947\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct BCL6B target genes mediating self-renewal not identified\", \"Contrast with tumor-suppressor role in other tissues unexplained\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified BCL6B as a tumor suppressor in carcinomas, activating p53 signaling to induce apoptosis and cell-cycle arrest and sensitize to 5-FU.\",\n      \"evidence\": \"Re-expression after demethylation and ectopic expression in HCC and colorectal lines, p53-pathway readouts, flow cytometry, invasion assays\",\n      \"pmids\": [\"25909168\", \"25973304\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"p53 activation shown by protein expression, not direct promoter assay in these studies\", \"EGR1 intermediary not mechanistically dissected\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Extended tumor-suppressor mechanism to PI3K/AKT inhibition, reducing cyclin D1/MMP-9 and restoring E-cadherin in colorectal cells.\",\n      \"evidence\": \"BCL6B transfection with pAKT readout and LY294002 co-treatment, proliferation and migration assays\",\n      \"pmids\": [\"29393377\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect effect on PI3K/AKT not distinguished\", \"Single-lab, no in vivo validation\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Provided direct promoter-level proof of the BCL6B/BCL6 antagonism: BCL6B binds and transactivates TP53 while repressing BCL6, and is upregulated by ZBTB16.\",\n      \"evidence\": \"ChIP and luciferase reporters on p53/BCL6 promoters, ZBTB16-ZBTB28 Co-IP, xenografts\",\n      \"pmids\": [\"31754389\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether p53 transactivation requires HDAC complex or is repressor-independent unclear\", \"Genome-wide occupancy not mapped\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Reinforced the ZBTB16-BCL6B partnership as a tumor-suppressive axis antagonizing BCL6 to reverse EMT in breast cancer.\",\n      \"evidence\": \"Reciprocal Co-IP, luciferase, xenografts, migration/invasion/colony assays\",\n      \"pmids\": [\"32517789\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct EMT target genes not defined\", \"Single-lab confirmation\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected BCL6B to autophagy-dependent apoptosis through FIP200 interaction and Bcl-XL degradation, disrupting the Bcl-XL–BECN1 complex.\",\n      \"evidence\": \"Ectopic ZBTB28 expression, EM autophagosome detection, interaction/Co-IP, xenograft, flow cytometry\",\n      \"pmids\": [\"33931087\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking transcriptional repressor to Bcl-XL degradation unresolved\", \"FIP200 binding interface undefined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Implicated BCL6B in innate immune surveillance by regulating IFNAR transcription and downregulating anti-phagocytic CD24/CD47 to promote macrophage phagocytosis.\",\n      \"evidence\": \"Ectopic ZBTB28 expression, IFNAR/ISG expression, flow cytometry, phagocytosis assay, xenograft\",\n      \"pmids\": [\"35048182\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct promoter binding to IFNAR not confirmed\", \"Relative contributions of CD24 vs CD47 unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Confirmed the angiogenic VEGF–BCL6B–Notch axis in retinal disease, where BCL6B loss activates Notch and BCL6B siRNA suppresses neovascular pathology.\",\n      \"evidence\": \"Knockout mice and siRNA in choroidal neovascularization and blood-retinal barrier models, CBF1/NICD readouts, monkey CNV model\",\n      \"pmids\": [\"37078291\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Therapeutic window and off-target effects of BCL6B knockdown unaddressed\", \"Interplay of E3 ligase and repressor functions in this setting unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed BCL6B gates endothelial cell fate by directly repressing the master EC factor ETV2, with ETV2 overexpression rescuing the differentiation block.\",\n      \"evidence\": \"Inducible hiPSC over/knockdown, ETV2 promoter ChIP-PCR and luciferase, RNA-seq, tube formation, vessel organoids, genetic rescue\",\n      \"pmids\": [\"39075623\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream signals controlling BCL6B in this program not defined\", \"Whether ETV2 repression uses BCL6/HDAC machinery untested\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Defined a direct BCL6B–GGT5 repression event reshaping MAPK signaling toward apoptosis and arrest in AML, with direct DNA binding confirmed.\",\n      \"evidence\": \"Dual-luciferase, EMSA, RNA-seq, ERK/p38/JNK westerns, gain/loss-of-function in AML, zebrafish and mouse xenografts\",\n      \"pmids\": [\"42083053\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How GGT5 loss biases MAPK branch selection mechanistically unclear\", \"Whether GGT5 axis operates outside AML untested\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Established post-translational control of BCL6B localization: ABHD17C depalmitoylation at Cys442 blocks importin-α/β nuclear import and triggers cytoplasmic degradation, derepressing CD24 for immune evasion.\",\n      \"evidence\": \"ABHD17C over/knockdown, palmitoylation and Cys442 mutagenesis, fractionation, importin Co-IP, ubiquitination assay, CD24 reporter, phagocytosis assay, orthotopic xenograft\",\n      \"pmids\": [\"42154583\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The palmitoyltransferase opposing ABHD17C not identified\", \"Whether this regulation generalizes beyond pancreatic cancer untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how BCL6B's distinct activities — BCL6-dependent transcriptional repression, BCL6-independent promoter transactivation of TP53, and CUL3-dependent E3 ligase function — are partitioned across cell types and whether common structural determinants or post-translational signals select between them.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural model integrating repressor and E3-adaptor roles\", \"Genome-wide occupancy and direct target catalog incomplete\", \"Context-switch between tumor-suppressor and self-renewal/tumorigenic roles unexplained\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 11, 16, 17]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 11, 16, 17]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [6]},\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 18]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 11, 16, 17]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 10, 15, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 5, 14]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [6, 15, 16]}\n    ],\n    \"complexes\": [\n      \"BCL6B-CUL3 E3 ubiquitin ligase complex\",\n      \"mSin3A/HDAC1 co-repressor complex (recruited via BCL6)\"\n    ],\n    \"partners\": [\n      \"BCL6\",\n      \"CUL3\",\n      \"CBF1\",\n      \"ZBTB16\",\n      \"FIP200\",\n      \"ABHD17C\",\n      \"KPNA (importin-alpha)\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}